Oncogenic driver mutations, treatment, and EGFR-TKI resistance in a Caucasian population with non-small cell lung cancer: survival in clinical practice.

about

BRAF inhibitors in metastatic non-small cell lung cancer.

P2860

Q55334153-6B19A3EB-D47F-4203-96B7-7538B0A668AC

P2860

Oncogenic driver mutations, treatment, and EGFR-TKI resistance in a Caucasian population with non-small cell lung cancer: survival in clinical practice.

Item

http://www.wikidata.org/entity/Q47147399

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Oncogenic driver mutations, tr ...... survival in clinical practice.

@en

Oncogenic driver mutations, tr ...... survival in clinical practice.

@nl

type

Item

label

Oncogenic driver mutations, tr ...... survival in clinical practice.

@en

Oncogenic driver mutations, tr ...... survival in clinical practice.

@nl

prefLabel

Oncogenic driver mutations, tr ...... survival in clinical practice.

@en

Oncogenic driver mutations, tr ...... survival in clinical practice.

@nl

P1476

Oncogenic driver mutations, tr ...... survival in clinical practice.

@en

P2093

Albrecht Stenzinger

http://www.w3.org/2001/XMLSchema#string

Birgit Schwenk

http://www.w3.org/2001/XMLSchema#string

Jörn Sträter

http://www.w3.org/2001/XMLSchema#string

Martin Faehling

http://www.w3.org/2001/XMLSchema#string

Robert Eckert

http://www.w3.org/2001/XMLSchema#string

Sebastian Kramberg

http://www.w3.org/2001/XMLSchema#string

P2860

First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer

Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy

Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.

Ceritinib in ALK-rearranged non-small-cell lung cancer.

P304

77897-77914

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.20857

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

A-L Volckmar

P577

2017-09-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29100434

http://www.w3.org/2001/XMLSchema#string

P932

5652823

http://www.w3.org/2001/XMLSchema#string

Oncogenic driver mutations, treatment, and EGFR-TKI resistance in a Caucasian population with non-small cell lung cancer: survival in clinical practice.

about

P2860

P2860

Oncogenic driver mutations, treatment, and EGFR-TKI resistance in a Caucasian population with non-small cell lung cancer: survival in clinical practice.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932